| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_115f2645d5ff1ca34c3c9f5a6e600714
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00e6543b49c5e8e48c48ee02c4759a53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_803195f16a0b73fb5caf56407bfc5793 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 |
| filingDate |
2000-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d921ba5ad86e547af482785c2d542a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89567a668c7cebe691d9e2b0b05d90e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9fa50fb147c144bcf22c626d397c51 |
| publicationDate |
2001-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0072820-A3 |
| titleOfInvention |
Injectable anesthetic formulation |
| abstract |
An injectable anesthetic formulation. The formulation contains a halogenated anesthetic in an amount not greater than approximately 24 % v/v of the formulation and an emulsification adjuvant in an amount from approximately 8 % to approximately 32 % v/v of the formulation. In addition, the formulation contains lecithin in an amount from approximately 1.2 % to approximately 2.4 % w/v of the formulation and a co-emulsifier in an amount not greater than approximately 1 % w/v of the formulation. |
| priorityDate |
1999-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |